About Aviceda Therapeutics
Aviceda Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2018 by Christopher Scott, Michael Tolentino, Derek Kunimoto, and Mohamed Genead. Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas. Aviceda Therapeutics has raised $254.66 million across 5 funding rounds from investors including Marshall Wace, abrdn and Orbimed. Its chief executive, as recorded, is Mohamed Genead. Aviceda Therapeutics offers products and services including Selective Ligands and Pipeline Programs. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its competitors include Moderna, BeiGene and Biogen; 3 of its 3 listed competitors have raised funding.
Company details
Aviceda Therapeutics was founded in 2018 and is based in Cambridge, United States. Biotherapeutics targeting glycol-immune diseases are developed, with a pipeline focused on eye diseases, fibrosis, neurology, and oncology. Specific candidates include AVD-104 and AVD-302 for dry eye and diabetic retinopathy, AVD-401 for retinoblastoma, AVD-601 for oncology, AVD-701 for neurology, and AVD-801 for fibrosis. Operations center on advancing these therapies through clinical development.
- Headquarters Cambridge, United States
- Founders Christopher Scott, Michael Tolentino, Derek Kunimoto, Mohamed Genead
- SectorsHealthcare
- Phone•••• ••••
- Website avicedarx.com
- Social LinkedIn X
- Total Equity Funding$254.66M (USD)
in 5 rounds
- Latest Funding Round$207.5M (USD), Series C
Dec 2024
- InvestorsMarshall Wace
& 11 more
Products & Services of Aviceda Therapeutics
Aviceda Therapeutics offers a comprehensive portfolio of products and services, including Selective Ligands and Pipeline Programs.
Compounds designed for precise immune modulation in inflammation and diseases.
Development of therapies targeting immune cells for various immunologic conditions.
Funding Insights of Aviceda Therapeutics
Aviceda Therapeutics has successfully raised a total of $254.66M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $207.5 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $254.66M
- Total Rounds 5
- Last Round Series C — $207.5M
- First Round $4.25M
(Sep 2020)
- Investors Count 12
All 5 funding rounds of Aviceda Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $207.5M | Series C | – | Omega Funds | |
| May 2024 | $18.9M | Series C | – | – | – |
| May 2023 | $15.61M | Series B | – | – | – |
| Mar 2022 | $8.4M | Series B | – | – | – |
| Sep 2020 | $4.25M | Series A | – | – | – |
12 investors in total: 12 institutional.
Investors in Aviceda Therapeutics
Aviceda Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Marshall Wace, abrdn and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm | omegafunds.com | Boston, United States | ||
| tcgcrossover.com | ||||
Jeito Capital is focused on financing medical innovation globally. | jeito.life | Paris, France | ||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Digitalis Ventures is engaged in health-focused investments. | digitalisventures.com | New York, United States | ||
Multiple sectors are invested in by abrdn's private equity fund. | 1825 | abrdn.com | Edinburgh, United Kingdom |
Investor details for Aviceda Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aviceda Therapeutics
34 people are tracked at Aviceda Therapeutics (11 in leadership, 20 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Christopher Scott | Co-Founder | Leadership |
Michael Tolentino | Co-Founder & CSO | Leadership |
Derek Kunimoto | Co-Founder & COO | Leadership |
Mohamed Genead | Co-Founder & CEO | Leadership |
Sunny Christian | Associate Director: Technology Development & Quality | Leadership |
Amitkumar Lad | Director, CMC (head) | Leadership |
Kinkini Roy | Associate Director, Drug Product Development | Leadership |
Tarek S. Hassan | SVP & Chief Development Officer | Leadership |
Keri Marchitto | Director, Clinical Operations | Leadership |
David Callanan | SVP & Chief Medical Officer | Leadership |
Ravinder E. | Associate Director | Leadership |
Geert-Jan Boons | Scientific & Clinical Advisor | Board & advisors |
Carl Regillo | Scientific & Clinical Advisor | Board & advisors |
Pamela Stanley | Chair of Scientific Board | Board & advisors |
Baruch D. Kuppermann | Clinical Advisor | Board & advisors |
Robert L. Avery | Clinical Advisor | Board & advisors |
Yvette Van Kooyk | Scientific & Clinical Advisor | Board & advisors |
Linus Ho | Scientific & Clinical Advisor | Board & advisors |
Chris Adams | Director | Board & advisors |
Jeffrey S. Heier | Scientific & Clinical Advisor | Board & advisors |
14 more people are available in the full profile.
Complete people profiles for Aviceda Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aviceda Therapeutics
3 dated milestones of Aviceda Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Aviceda Therapeutics is founded.
- Funding First funding round of $4.2M.
- Funding Latest funding round, Series C, of $207.5M.
Competitors of Aviceda Therapeutics
Aviceda Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Biogen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. |
Detailed competitors of Aviceda Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aviceda Therapeutics
The website of Aviceda Therapeutics (avicedarx.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▼ 40.3% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Aviceda Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aviceda Therapeutics
Complete news archive for Aviceda Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aviceda Therapeutics
Aviceda Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Aviceda Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Mohamed Genead is the CEO of Aviceda Therapeutics, as recorded in our data. They have also founded this company.
Aviceda Therapeutics is a funded company, having raised a total of $254.66M across 5 funding rounds to date. The company's 1st funding round was a Series A of $4.25M, raised on Sep 2020.
Aviceda Therapeutics was founded in 2018 and is based in Cambridge, United States. Biotherapeutics targeting glycol-immune diseases are developed, with a pipeline focused on eye diseases, fibrosis, neurology, and oncology. Specific candidates include AVD-104 and AVD-302 for dry eye and diabetic retinopathy, AVD-401 for retinoblastoma, AVD-601 for oncology, AVD-701 for neurology, and AVD-801 for fibrosis. Operations center on advancing these therapies through clinical development.
Aviceda Therapeutics offers Selective Ligands and Pipeline Programs.
Aviceda Therapeutics has 12 investors. Key investors include Marshall Wace, abrdn, Orbimed, Blue Owl, and Enavate Sciences.